NCT05923190 is a Phase 2 clinical trial of Enfortumab vedotin in Urothelial Carcinoma, sponsored by Fox Chase Cancer Center.

Who is sponsoring NCT05923190?

NCT05923190 is sponsored by Fox Chase Cancer Center.

What drugs are being tested in NCT05923190?

Interventions in NCT05923190: Enfortumab vedotin, Pembrolizumab.

What condition does NCT05923190 study?

NCT05923190 studies Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma.

Is NCT05923190 still recruiting?

NCT05923190 is currently active, enrolled. Last updated 19 March 2026.

Last reviewed 2026-03-19 · How we verify

NCT05923190

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

Active, enrolled Phase 2 Last updated 19 March 2026

What this trial tests

Phase 2 trial testing Enfortumab vedotin in Urothelial Carcinoma in 60 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

14 June 2023

Primary endpoint
1 July 2028

1 July 2029

Quick facts

Lead sponsor	Fox Chase Cancer Center
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	14 June 2023
Primary completion	1 July 2028
Estimated completion	1 July 2029
Sites	1 location across United States

Drugs / interventions tested

Enfortumab vedotin — full drug profile →
Pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

Urothelial Carcinoma — all drugs for Urothelial Carcinoma →
Metastatic Urothelial Carcinoma — all drugs for Metastatic Urothelial Carcinoma →
Locally Advanced Urothelial Carcinoma — all drugs for Locally Advanced Urothelial Carcinoma →

Sponsor

Fox Chase Cancer Center — full company profile →

Who can join

18 and older, any sex, with Urothelial Carcinoma or Metastatic Urothelial Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a non-randomized two arm open-label phase 2 pilot study in adult subjects with locally advanced or metastatic urothelial cancer. The study will investigate an alternative administration schedule of EV given as monotherapy and in combination with pembrolizumab.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives.
Testi I, Giudice GC, Salfi G, Pedrani M, et al · · 2024 · PMID 39764422 · DOI 10.37349/etat.2024.00279

Verify or expand the search:

Other trials of Enfortumab vedotin

Trials testing the same drug.

NCT07221942 — Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma · Phase 2 · recruiting
NCT06041503 — Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) · Phase 2 · recruiting
NCT07347314 — Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combi · Phase 2 · recruiting
NCT06394570 — Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer · Phase 1, PHASE2 · recruiting
NCT05915351 — Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) · Phase 2 · active not recruiting

Other recruiting trials for Urothelial Carcinoma

Currently open trials in the same condition.

NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
NCT07421700 — Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer · Phase 1, PHASE2 · recruiting
NCT07492628 — Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma · Phase 1 · recruiting
NCT07390617 — A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma · recruiting

Other Fox Chase Cancer Center trials

Trials by the same sponsor.

NCT07455032 — Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous · Phase 1 · recruiting
NCT07221942 — Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma · Phase 2 · recruiting
NCT07221058 — Adaptive Radiation Boost for Rectal Cancer · Phase 1 · recruiting
NCT07167446 — Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy · EARLY_PHASE1 · recruiting
NCT07219303 — Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05923190 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fox Chase Cancer Center
Last refreshed: 19 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05923190.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing